ResearcherGerman Cancer Research CenterActive in the last 2 years
Christoph Roesli
Matched on ORCID iD 0000-0001-6182-5020; OpenAlex author ID A5016857255. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 16
2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 3
- Proteomic Characterization Reveals CYP2S1 as a Mediator of Drug Resistance in PDAC. Last author DOI 10.1097/mpa.0000000000002553↗
- Identification and Validation of Novel Subtype-Specific Protein Biomarkers in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000000743↗
- CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/nm.4038↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Elisa M. Noll · 3 shared papers, 2016–2026 · strength 0.34
- Paper Proteomic Characterization Reveals CYP2S1 as a Mediator of Drug Resistance in PDAC. DOI 10.1097/mpa.0000000000002553↗
- Paper Identification and Validation of Novel Subtype-Specific Protein Biomarkers in Pancreatic Ductal Adenocarcinoma. DOI 10.1097/mpa.0000000000000743↗
- Paper CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. DOI 10.1038/nm.4038↗
- Martin Ronald Sprick · 3 shared papers, 2016–2026 · strength 0.34
- Paper Proteomic Characterization Reveals CYP2S1 as a Mediator of Drug Resistance in PDAC. DOI 10.1097/mpa.0000000000002553↗
- Paper Identification and Validation of Novel Subtype-Specific Protein Biomarkers in Pancreatic Ductal Adenocarcinoma. DOI 10.1097/mpa.0000000000000743↗
- Paper CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. DOI 10.1038/nm.4038↗
- Andreas Trumpp · 3 shared papers, 2016–2026 · strength 0.34
- Paper Proteomic Characterization Reveals CYP2S1 as a Mediator of Drug Resistance in PDAC. DOI 10.1097/mpa.0000000000002553↗
- Paper Identification and Validation of Novel Subtype-Specific Protein Biomarkers in Pancreatic Ductal Adenocarcinoma. DOI 10.1097/mpa.0000000000000743↗
- Paper CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. DOI 10.1038/nm.4038↗
- Laura Kuhlmann · 2 shared papers, 2017–2026 · strength 0.30
- Nathalia A. Giese · 2 shared papers, 2016–2026 · strength 0.27
- Thilo Hackert · 2 shared papers, 2016–2026 · strength 0.27
- Vera Thiel · 1 shared paper, 2026 · strength 0.23
- Elisa Espinet Espinet · 2 shared papers, 2016–2017 · strength 0.10
- Marcus Bahra · 1 shared paper, 2016 · strength 0.04
- Wilko Weichert · 1 shared paper, 2016 · strength 0.04
- Alexander Muckenhuber · 1 shared paper, 2016 · strength 0.04
- Bruno Valentin Sinn · 1 shared paper, 2016 · strength 0.04
- Markus Wolfgang Büchler · 1 shared paper, 2016 · strength 0.04
- Oliver Strobel · 1 shared paper, 2016 · strength 0.04
- Albrecht Stenzinger · 1 shared paper, 2016 · strength 0.04
- Jens Werner · 1 shared paper, 2016 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.